Ozagrel sodium

Overview

Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A 2 (TXA 2 ) synthase inhibitor with an IC 50 of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA 2 and increasing the production of prostacyclin (PGI2) . Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases.

Application

Products | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Coronavirus Infection | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Prostaglandin Receptor

Product Information

• Catalog No.: HY-B0428A
• CAS No.: 189224-26-8
• Molecular Formula: C13H11N2NaO2
• Molecular Weight: 250.23
• Purity: 99.82%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 0.62 mg/mL (2.48 mM); Clear solution
• Availability: In-stock

Source

Original product source